We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urinary Assay for Alzheimer's Disease Verified by Clinical Studies

By Labmedica staff writers
Posted on 14 Jan 2008
A urinary assay adds significant useful information in the diagnosis of Alzheimer's disease (AD), particularly for the family physician.

AlzheimAlert is a non-invasive accurate urine test that can help in the diagnosis of AD. More...
The AlzheimAlert test detects the presence of a brain protein--neural thread protein (NTP)--which is elevated in the urine of patients with Alzheimer's disease.

The test AlzheimAlert was developed and produced by Nymox Pharmaceutical Corp. (Hasbrouck Heights, NJ, USA). A positive report on AlzheimAlert was published in the January 2008 issue of the journal Expert Review of Molecular Diagnostics. The article was written by Ira Goodman, M.D., director of neurology, Orlando Regional HealthCare, Florida (Orlando, FL, USA) and associate clinical professor, departments of neurology and medicine, University of Florida School of Medicine (Gainesville, FL, USA). The article reviews the large number of basic research and clinical studies to date concerning the accuracy and specificity of the Nemox's urinary assay and documents several of Dr. Goodman's own clinical cases where the assay results proved useful in either arriving at a diagnosis of AD or in helping to rule it out.

One report involved a 39-year-old year male with an elevated AlzheimAlert result supportive of an AD diagnosis. Extensive testing confirmed a rare form of familial AD. A second of the researcher's cases involved a 54-year-old male with a history of cognitive decline and an elevated AlzheimAlert result. Eventually, a brain biopsy confirmed the diagnosis. In other cases described in the article, negative AlzheimAlert results helped to lead to other diagnoses, which were not AD.

The test has the CE Mark, allowing it to be marketed in Europe, and is also available to physicians in the United States through the company's Clinical Laboratory Improvement Amendments- (CLIA)-approved clinical reference laboratory. Data showing the high clinical accuracy and utility of the test have been frequently reported in the peer-reviewed literature, including the Journal of Clinical Laboratory Analysis (Volume 8, 2007) and the Journal of the American Medical Directors Association (Volume 21, 2007).


Related Links:
Orlando Regional HealthCare
University of Florida School of Medicine
Nymox Pharmaceutical Corp

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.